Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TPO | P07202 | 1/20 | 0.31 |
| ▸ | EPX | P11678 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542130 | 0.82 | MPO (0.35) | GCKMPOTPOEPXLPO | |
| SCHEMBL3547701 | 0.80 | GCK (0.31) | GCK | |
| SCHEMBL3544609 | 0.78 | S1PR4 (0.38) | GCK | |
| SCHEMBL3545385 | 0.78 | GCK (0.35) | GCK | |
| SCHEMBL3540373 | 0.74 | GCK (0.36) | GCKP2RX3 | |
| SCHEMBL2646549 | 0.72 | GCK (0.36) | GCKMPOTPOEPXLPO | |
| SCHEMBL3548140 | 0.71 | GCK (0.47) | GCK | |
| SCHEMBL2645285 | 0.69 | GCK (0.35) | GCK | |
| SCHEMBL2645796 | 0.69 | MAPT (0.39) | GCK | |
| SCHEMBL2644356 | 0.68 | CACNA1C (0.39) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935890-B1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-7799820-B2 | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1935890-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | GCKR, GPR119, GCK | GCK 3/4885MPO 644/4885TPO 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.